209 (PB089) - Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1).
Saved in:
| Title: | 209 (PB089) - Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). |
|---|---|
| Authors: | Besse, B.1 (AUTHOR), Springfeld, C.2 (AUTHOR), Baik, C.3 (AUTHOR), Hervieu, A.4 (AUTHOR), Solomon, B.5 (AUTHOR), Moreno, V.6 (AUTHOR), Bazhenova, L.7 (AUTHOR), Goto, K.8 (AUTHOR), Kim, Y.C.9 (AUTHOR), Lu, S.10 (AUTHOR), Sun, M.11 (AUTHOR), Trone, D.12 (AUTHOR), Thamake, S.12 (AUTHOR), Cho, B.C.13 (AUTHOR), de Langen, A.14 (AUTHOR), Popat, S.15 (AUTHOR), Wolf, J.16 (AUTHOR), Moro-Sibilot, D.17 (AUTHOR), Fang, J.18 (AUTHOR), Drilon, A.19 (AUTHOR) |
| Source: | European Journal of Cancer. 2022 Supplement 1, Vol. 174, pS75-S76. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 159857261 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 209 (PB089) - Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Besse%2C+B%2E%22">Besse, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Springfeld%2C+C%2E%22">Springfeld, C.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Baik%2C+C%2E%22">Baik, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hervieu%2C+A%2E%22">Hervieu, A.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Solomon%2C+B%2E%22">Solomon, B.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moreno%2C+V%2E%22">Moreno, V.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bazhenova%2C+L%2E%22">Bazhenova, L.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Goto%2C+K%2E%22">Goto, K.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+Y%2EC%2E%22">Kim, Y.C.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lu%2C+S%2E%22">Lu, S.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sun%2C+M%2E%22">Sun, M.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Trone%2C+D%2E%22">Trone, D.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thamake%2C+S%2E%22">Thamake, S.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cho%2C+B%2EC%2E%22">Cho, B.C.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22de+Langen%2C+A%2E%22">de Langen, A.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Popat%2C+S%2E%22">Popat, S.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wolf%2C+J%2E%22">Wolf, J.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moro-Sibilot%2C+D%2E%22">Moro-Sibilot, D.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fang%2C+J%2E%22">Fang, J.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Drilon%2C+A%2E%22">Drilon, A.</searchLink><relatesTo>19</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Cancer%22">European Journal of Cancer</searchLink>. 2022 Supplement 1, Vol. 174, pS75-S76. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=159857261 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S0959-8049(22)01000-0 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S75 Titles: – TitleFull: 209 (PB089) - Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Besse, B. – PersonEntity: Name: NameFull: Springfeld, C. – PersonEntity: Name: NameFull: Baik, C. – PersonEntity: Name: NameFull: Hervieu, A. – PersonEntity: Name: NameFull: Solomon, B. – PersonEntity: Name: NameFull: Moreno, V. – PersonEntity: Name: NameFull: Bazhenova, L. – PersonEntity: Name: NameFull: Goto, K. – PersonEntity: Name: NameFull: Kim, Y.C. – PersonEntity: Name: NameFull: Lu, S. – PersonEntity: Name: NameFull: Sun, M. – PersonEntity: Name: NameFull: Trone, D. – PersonEntity: Name: NameFull: Thamake, S. – PersonEntity: Name: NameFull: Cho, B.C. – PersonEntity: Name: NameFull: de Langen, A. – PersonEntity: Name: NameFull: Popat, S. – PersonEntity: Name: NameFull: Wolf, J. – PersonEntity: Name: NameFull: Moro-Sibilot, D. – PersonEntity: Name: NameFull: Fang, J. – PersonEntity: Name: NameFull: Drilon, A. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 10 Text: 2022 Supplement 1 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09598049 Numbering: – Type: volume Value: 174 Titles: – TitleFull: European Journal of Cancer Type: main |
| ResultId | 1 |
